Baillie Gifford & Co
ARIA

Baillie Gifford & Co’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Baillie Gifford & Co’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,327
Closed -$98K – 219
2013
Q3 		$98K Hold
5,327
– – ﹤0.01% 201
2013
Q2 		$93K Buy
+5,327
New +$94.4K ﹤0.01% 177

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Baillie Gifford & Co's ARIA Position: Q4 2013 in Review

Baillie Gifford & Co sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2013, closing a stake of 5,327 shares — an estimated $98K sold.

Baillie Gifford & Co first reported a position in ARIA in Q2 2013 and held it in 2 quarters. The position peaked at $98K in Q3 2013. 166 funds tracked by Wall St. Rank hold ARIA as of Q4 2013.

  • Baillie Gifford & Co reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Baillie Gifford & Co sold 5,327 Ariad Pharmaceuticals Inc shares in Q4 2013, an estimated $98K.
  • Baillie Gifford & Co first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Baillie Gifford & Co's Ariad Pharmaceuticals Inc position peaked at $98K in Q3 2013.
  • 166 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2013.

Based on Baillie Gifford & Co's 13F filing for Q4 2013, filed 7 Feb 2014.